Advancement In Cuba-China’s Joint Vaccine Innovation

June 2 was the day that Cuba and China formally announced their intention to apply for a single vaccine against Pan-Corona viruses, which they claimed was the first patent for a single vaccine effective against many versions of COVID-19.

The news of the collaborative vaccine's development is particularly exciting because of the two nations' collaborative approach in a field that is extremely competitive, secretive, and entirely profit-oriented in Western capitalist nations.

The development of new antiviral treatments has been a breakthrough.

The Pan-Corona vaccine was declared to be effective against current variants of COVID-19, making it useful in the current outbreak. (Eduardo Martínez Díaz, president of the state-owned BioCubaFarma Business Group) Its advantage is that it may also combat future viruses from this family of viruses,

The Pan-Corona project is based in a biotechnology research and development center established in Yongzhou, Hunan province, China, since 2019 and headed by Cuban scientists from the Center for Genetic Engineering and Biotechnology (CIGB). Dr. Gerardo Guillén Nieto, Head of Health Research and Tech.

The two countries had been studying coronaviruses owing to the worldwide pandemic and because this is the family of viruses most likely to jump from animals to humans. This phenomenon, also known as zoonosis, was responsible for previous epidemics such as the 2002 SARS epidemic and the 2012 MERS outbreak — both severe respiratory diseases caused by animal